Showing 1821-1830 of 2494 results for "".
- FDA Probes Whether to Allow AstraZeneca to Resume COVID-19 Vaccine Trial in UShttps://modernod.com/news/fda-probes-whether-to-allow-astrazeneca-to-resume-covid-19-vaccine-trial-in-us/2478286/The FDA is looking into whether they should follow their UK counterparts in allowing a phase 3 study of AstraZeneca’s COVID-19 vaccine to resume after it had been temporarily suspended last week when a trial participant in the UK was said to have suffered spinal cord inflammation. AstraZene
- Staar Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trialhttps://modernod.com/news/staar-surgical-announces-completion-of-patient-enrollment-in-evo-implantable-lens-us-clinical-trial/2478275/Staar Surgical has announced that patient enrollment for the primary study analysis cohort of 300 subjects has been achieved in its FDA clinical trial, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian Implantable Collamer Lens.” Primary study analysis will be conducted when 300 primary e
- Americans See Hospitals as More Trustworthy Than FDA or CDC on COVID-19 Vaccine Information, Poll Findshttps://modernod.com/news/americans-see-hospitals-as-more-trustworthy-than-fda-or-cdc-on-covid-19-vaccine-information-poll-finds/2478225/When it comes to getting information about a future COVID-19 vaccine, Americans see hospitals as more trustworthy sources than federal agencies like the Food and Drug Administration or the Centers for Disease Control and Prevention (CDC), according to a new poll, as
- Hadley Launches New Website For Those Facing Vision Losshttps://modernod.com/news/hadley-launches-new-website-for-those-facing-vision-loss/2478068/In 1920, William Hadley, a Chicago area high school teacher who lost his sight at the age of 55, revolutionized the way adults facing vision loss would learn to read again when he created his Braille by Mail system. One hundre
- Study Points to Potential New Approach to Treating Glaucoma and Alzheimer’s Diseasehttps://modernod.com/news/study-points-to-potential-new-approach-to-treating-glaucoma-and-alzheimers-disease/2478060/Researchers at Vanderbilt University Medical Center (VUMC) have shown for the first time that when one optic nerve in the eye is damaged, as in glaucoma, the opposite optic nerve comes to the rescue by sharing its metabolic energy. In doing so, however, the undamaged optic nerve becomes vu
- Glaucoma Study Findings Emphasize Need for Regular Eye Checkshttps://modernod.com/news/glaucoma-study-findings-emphasize-need-for-regular-eye-checks/2478048/People with early-stage glaucoma see the contrast of visible objects in a very similar way to people without the condition, a new study has shown. Research by the University of Bradford (UK) demonstrated that the brain compensates for the changes in the eye caused by glaucoma, when looking
- Apple Was Already Developing Handwashing Sensing Before COVID-19 Hithttps://modernod.com/news/apple-was-already-developing-handwashing-sensing-before-covid-19-hit/2477981/When Apple vice president of technology Kevin Lynch announced at WWDC last week that Apple Watch would add an automatic handwashing-detection feature in its next update, many people naturally assumed the feature was prompted by the COVID-19 pandemic – a public health emergency that has strongly u
- Santen Announces FDA Acceptance of Premarket Approval Application for DE-128 (MicroShunt) for Reviewhttps://modernod.com/news/santen-announces-fda-acceptance-of-premarket-approval-application-for-de-128-microshunt-for-review/2477976/Santen Pharmaceutical announced that the FDA has accepted the premarket approval (PMA) application for DE-128 (MicroShunt) for review. DE-128 is an investigational surgical glaucoma implant designed to reduce IOP in patients with primary open-angle glaucoma whose IOP is not controlled when using
- Sanofi, Regeneron’s Kevzara Fails Late-Stage Study in COVID-19https://modernod.com/news/sanofi-regenerons-kevzara-fails-late-stage-study-in-covid-19/2477966/Sanofi and Regeneron Pharmaceuticals announced Thursday that a phase 3 trial of their rheumatoid arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when the IL-6 receptor antibody was added to best s
- 2021 ASCRS Annual Meeting Pushed Back to Augusthttps://modernod.com/news/2021-ascrs-annual-meeting-pushed-back-to-august/2477939/ASCRS announced that it is pushing back its 2021 annual meeting in San Francisco from April to August. “This decision was thoroughly researched and discussed, and when weighed against the risks of possibly losing another meeting to the coronavirus, we felt we had no other alternative